Drugs / Recombinant Influenza HA Vaccine (H5N1)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01195038 | Oct 2010 → Jan 2011 | influenza | UMN Pharma Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-03-13 | Astellas Pharma Inc | Results Immunogenicity and Favorable Tolerability Observed in Phase II Clinical Trial for H5N1 Influenza Vaccine ASP7373 astellas.com ↗
Astellas and UMN are happy to announce that immunogenicity and favorable tolerability have been observed, and no serious adverse events have been reported. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-03-13 | Astellas Pharma Inc | Immunogenicity and Favorable Tolerability Observed in Phase II Clinical Trial for H5N1 Influenza Vaccine ASP7373 astellas.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Influenza HA Vaccine (H5N1) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01195038 ↗ |
| Modality | Vaccine | “recombinant H5N1 influenza (A/Indonesia/05/2005) HA vaccine” NCT01195038 ↗ |